Springfield Clinic, LLP v. Primex Clinical Laboratories, Inc.

CourtDistrict Court, C.D. California
DecidedApril 29, 2022
Docket2:21-cv-03595
StatusUnknown

This text of Springfield Clinic, LLP v. Primex Clinical Laboratories, Inc. (Springfield Clinic, LLP v. Primex Clinical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Springfield Clinic, LLP v. Primex Clinical Laboratories, Inc., (C.D. Cal. 2022).

Opinion

Case 2:21-cv-03595-RSWL-AS Document 77 Filed 04/29/22 Page 1 of 16 Page ID #:628 'O' 1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 CENTRAL DISTRICT OF CALIFORNIA 10 11 CV 21-03595-RSWL-ASx 12 SPRINGFIELD CLINIC, LLP, ORDER re: MOTION TO 13 Plaintiff, DISMISS FIRST AMENDED 14 v. COUNTERCLAIM [71] 15 PRIMEX CLINICAL 16 LABORATORIES, INC., 17 Defendant. 18 PRIMEX CLINICAL 19 LABORATORIES. INC., 20 Third-Party Plaintiff, 21 v. 22 23 TBS BUSINESS SOLUTIONS USA INC.; and TEWODROS SAHILU, 24 Third-Party Defendants. 25 26 27 28 1 Case 2:21-cv-03595-RSWL-AS Document 77 Filed 04/29/22 Page 2 of 16 Page ID #:629

1 TBS BUSINESS SOLUTIONS USA INC., 2 Counterclai m-Plaintiff, 3 v. 4 5 PRIMEX CLINICAL LABORATORIES INC.; STUDEBAKER DEFENSE 6 GROUP, LLC; GLENN HILL; TOM MARX; and ROES 1 to 10, 7 8 Counterclaim-Defendants. 9 10 Springfield Clinic, LLP (“Springfield”) initiated 11 this Action on April 28, 2021, against Primex Clinical 12 Laboratories, Inc. (“Primex”). Primex then filed a 13 third-party complaint (“Primex Complaint”) against TBS 14 Business Solutions USA Inc. (“TBS”) on July 7, 2021. 15 TBS then filed a third-party complaint against Glen 16 Hill, Tom Marx, and Studebaker Defense Group, LLC 17 (collectively, “Studebaker Defendants”) on October 5, 18 2021. After the Court granted Studebaker Defendants’ 19 motion to dismiss TBS’s third-party complaint, TBS 20 amended its Answer to the Primex Complaint to include 21 counterclaims against Studebaker Defendants. Currently 22 before the Court is Studebaker Defendants’ Motion to 23 Dismiss TBS’s First Amended Counterclaim (the “Motion”). 24 Having reviewed all papers submitted pertaining to this 25 Motion, the Court NOW FINDS AND RULES AS FOLLOWS: the 26 Court GRANTS the Motion. 27 /// 28 /// 2 Case 2:21-cv-03595-RSWL-AS Document 77 Filed 04/29/22 Page 3 of 16 Page ID #:630

1 I. BACKGROUND

2 A. Factual Background

3 Springfield is a multi-specialty physician practice 4 that provides health care to the central Illinois 5 community. Compl. (“Springfield Compl.”) ¶ 6, ECF No. 6 1. Around April 2020, Springfield contracted with 7 Primex, a clinical laboratory that provides diagnostic 8 services, for Primex to provide Springfield with 1 9 million 3M-branded N95 masks. Id. ¶¶ 10-11. 10 Through April, May, and June of 2020, Primex 11 entered into a series of transactions to purchase 1 12 million 3M masks from TBS, a supplier and distributor of 13 various products. Third-Party Compl. (“Primex Compl.”) 14 ¶¶ 14, 17-18, ECF No. 14. TBS allegedly represented to 15 Primex that it would give Primex priority in the 16 allocation of masks because Primex was a first 17 responder, and TBS could obtain 3M products quicker than 18 any other wholesaler. Id. ¶ 18. Thus, Primex tendered 19 the sum of $970,000 to TBS in exchange for 1 million 3M 20 masks.1 Id. ¶ 19. However, TBS failed to deliver masks 21 to Primex sufficient to satisfy any of Primex’s purchase 22 orders. Id. ¶ 20. TBS satisfied only a portion of a 23 purchase order in some instances, and it offered a 24

25 1 Primex also ordered masks from TBS to fill purchase orders other than the Springfield purchase order. Id. ¶ 17. In 26 particular, Primex placed an additional order with TBS for 1.5 million masks in exchange for $1,455,000. Id. Primex is seeking 27 recovery from TBS for those additional orders in this suit as well, bringing its damages request to a total of $2,220,731.20. 28 Id. ¶ 17 Table 1; id. Prayer for Relief. 3 Case 2:21-cv-03595-RSWL-AS Document 77 Filed 04/29/22 Page 4 of 16 Page ID #:631

1 substitute product to fill the order in others. Id.

2 ¶¶ 21, 23. TBS also refunded Primex a portion of the

3 money it had paid. Id. ¶ 22. However, Primex alleges 4 that TBS refuses to either perform its remaining 5 obligations under their contract or to refund Primex the 6 remaining balance it is owed. Id. ¶ 25. 7 Meanwhile, when TBS was unable to obtain 3M masks 8 through other suppliers, it sought to fulfill the Primex 9 order through Studebaker Defense Group, LLC 10 (“Studebaker”). TBS First Am. Countercl. to Primex 11 Compl. (“TBS FACC”) ¶¶ 17-19, ECF No. 60. Studebaker 12 allegedly represented that it could supply TBS with 1 13 million Honeywell-branded masks by November 20, 2020, 14 and with 1.5 million Honeywell-branded masks by January 15 15, 2020. Id. ¶ 18. In reliance on this 16 representation, on October 19, 2020, TBS ordered 1 17 million masks from Studebaker at a cost of $960,000, to 18 be delivered on November 20, 2020 (“PO1”). Id. ¶ 19. 19 TBS cancelled pending orders it had placed with other 20 suppliers. Id. ¶ 20. On November 23, 2020, TBS learned 21 that Honeywell had informed Studebaker that PO1 may not 22 be fulfilled until as late as March 1, 2021. Id. ¶ 21. 23 TBS and Primex consequently entered into revised 24 purchase orders that reflected a later delivery date. 25 Id. ¶ 22. TBS paid Studebaker $960,000 for PO1 on 26 December 2, 2020. Id. ¶ 24. 27 On December 4, 2020, TBS ordered 1.5 million 28 Honeywell masks from Studebaker at a cost of $1,440,000, 4 Case 2:21-cv-03595-RSWL-AS Document 77 Filed 04/29/22 Page 5 of 16 Page ID #:632

1 to be delivered by January 15, 2021 (“PO2”). Id. ¶ 26.

2 TBS paid Studebaker for PO2 on December 8, 2020. Id.

3 After several discussions between TBS and Studebaker and 4 a partial fulfillment of the order, however, Studebaker 5 failed to supply TBS with masks sufficient to fill PO1 6 or PO2 by the specified dates. Id. ¶¶ 27-32. On April 7 16, 2021, Primex demanded that its revised orders with 8 TBS be cancelled, and TBS requested that Studebaker 9 cancel PO2 that same day. Id. ¶ 33. Studebaker then 10 informed TBS that the outstanding mask deliveries for 11 both PO1 and PO2 would soon be ready to ship. Id. ¶¶ 12 35. TBS did not receive these shipments, and on May 20, 13 2021, TBS reached out to Honeywell directly regarding 14 PO1 and PO2. Id. ¶ 37. Honeywell allegedly informed 15 TBS that it had fulfilled all of Studebaker’s purchase 16 orders. Id. TBS contends that Studebaker has delivered 17 only $260,000 worth of masks and that TBS has thus 18 suffered damages in excess of $2,180,000. Id. ¶¶ 58-59. 19 B. Procedural Background 20 Springfield initiated this Action [1] on April 28, 21 2021, against Primex. Primex impleaded TBS and filed a 22 third-party complaint (“Primex Complaint”) [14] against 23 TBS on July 7, 2021. TBS then impleaded Studebaker 24 Defendants and filed a third-party complaint (“TBS 25 Complaint”) [29] against them on October 5, 2021. 26 Studebaker Defendants moved to dismiss [49] the TBS 27 Complaint on December 1, 2021. The Court granted [57] 28 Studebaker Defendants’ motion on January 6, 2022, 5 Case 2:21-cv-03595-RSWL-AS Document 77 Filed 04/29/22 Page 6 of 16 Page ID #:633

1 concluding that TBS had improperly joined Studebaker

2 Defendants to this Action under Rule 14 of the Federal

3 Rules of Civil Procedure. With its third-party 4 complaint dismissed, TBS then amended [60] its Answer to 5 the Primex Complaint on January 19, 2022, to include 6 counterclaims (“FACC”) against Studebaker Defendants 7 that are nearly identical to the claims it had alleged 8 against Studebaker Defendants in the TBS Complaint. 9 Studebaker Defendants filed the instant Motion to 10 Dismiss [71] on March 29, 2022. TBS opposed [72] the 11 Motion to Dismiss on April 5, 2022. Studebaker 12 Defendants replied [73] on April 12, 2022. 13 II. DISCUSSION 14 A. Legal Standard 15 1. Rule 13(h) 16 Rule 13(h) of the Federal Rules of Civil Procedure 17 allows for new parties to be joined to an action by 18 adding them to a counterclaim or crossclaim.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Jackson v. Birmingham Board of Education
544 U.S. 167 (Supreme Court, 2005)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. Hiram Webb
655 F.2d 977 (Ninth Circuit, 1981)
Coughlin v. Rogers
130 F.3d 1348 (Ninth Circuit, 1997)
Various Markets, Inc. v. Chase Manhattan Bank, N.A.
908 F. Supp. 459 (E.D. Michigan, 1995)
Natural Resources Defense Council v. Kempthorne
539 F. Supp. 2d 1155 (E.D. California, 2008)
Rank v. (Krug) United States
142 F. Supp. 1 (S.D. California, 1956)
Wynn v. National Broadcasting Co., Inc.
234 F. Supp. 2d 1067 (C.D. California, 2002)
Alltech Communications, LLC v. Brothers
601 F. Supp. 2d 1255 (N.D. Oklahoma, 2008)
Wallace v. Maples
14 P. 19 (California Supreme Court, 1887)
Spengler Core Drilling Co. v. Spencer
10 F.2d 579 (S.D. California, 1926)

Cite This Page — Counsel Stack

Bluebook (online)
Springfield Clinic, LLP v. Primex Clinical Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/springfield-clinic-llp-v-primex-clinical-laboratories-inc-cacd-2022.